Safety and efficacy of a ten day helicobacter pylori eradication regimen with rabeprazole, amoxicillin and clarithromycin. (c2003)

Abstract

OBJECTIVE: We assessed the safety and efficacy of a 1 a-day twice daily rabeprazole-based triple therapy for Helicobacler pylori (H .pylon). METHODS: H. pylori infected patients as confirmed by a rapid urease test were enrolled in an outpatient based open-label prospective trial. Symptomatic H. pylori infected patients were assigned to receive amoxicillin 1000 mg, clarithromycin 500 mg and rabeprazole 20 mg all twice daily for 10 days. No maintenance therapy was given during the follow up period. Patients were followed up during therapy by telephone calls to assess compliance and any occurrence of adverse effects. The efficacy endpoint was assessed by using the 14_C urea breath test (UBT). Occurrence of side effects was also evaluated. RESULTS: A total of 104 patients were analyzed per intention-to-treat (ITT) and per-protocol (PP). Eradication rates of 87.5% (ITT) and 93.8% (PP) were obtained. Therapy was relatively well tolerated with minimal side effects. CONCLUSION: Rabeprazole-based triple therapy is a suitable regimen for eradication of H. pylori infection.